MSMark A. Sussman

Mark A. Sussman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark A. Sussman has a total of 32 co-authors. Here are the top co-authors by number of shared publications:

  • Robert L. Price

    The Children’s Hospital and Research Foundation, Division of Molecular Cardiovascular Biology, Cincinnati, Ohio 45229, USA2University of South Carolina, Department of Developmental Biology and Anatomy, University of South Carolina School of Medicine, Columbia, South Carolina 29208, USA3QCB Biosource International, 3 Avenue D, Hopkinton, Massachusetts 01748, USA4The Children’s Hospital and Research Foundation, Transgenic Core Facility, Cincinnati, Ohio 45229, USA

    3 shared publications
  • Sara Welch

    From the Divisions of Molecular Cardiovascular Biology (D.C.-K., S.W., A.W., I.S., M.A.S.) and Clinical Mass Spectrometry (K.D.R.S.), The Children’s Hospital Research Foundation, Cincinnati, Ohio; Biosource International (E.S.), Hopkinton, Mass; and Cardiovascular Research Institute (J.K., P.A.), New York Medical College, Valhalla, NY

    3 shared publications
  • Angela Walker

    From the Divisions of Molecular Cardiovascular Biology (D.C.-K., S.W., A.W., I.S., M.A.S.) and Clinical Mass Spectrometry (K.D.R.S.), The Children’s Hospital Research Foundation, Cincinnati, Ohio; Biosource International (E.S.), Hopkinton, Mass; and Cardiovascular Research Institute (J.K., P.A.), New York Medical College, Valhalla, NY

    2 shared publications
  • Erik Schaefer

    From the Divisions of Molecular Cardiovascular Biology (D.C.-K., S.W., A.W., I.S., M.A.S.) and Clinical Mass Spectrometry (K.D.R.S.), The Children’s Hospital Research Foundation, Cincinnati, Ohio; Biosource International (E.S.), Hopkinton, Mass; and Cardiovascular Research Institute (J.K., P.A.), New York Medical College, Valhalla, NY

    2 shared publications
  • Chang-Sub Uhm

    1 shared publication
  • Darryl Kirkpatrick

    Division of Cardiology, University of Cincinnati, Cincinnati, Ohio

    1 shared publication

Latest Publications

  • Myocardial Akt Activation and Gender

    by Dreama Camper-Kirby, Sara Welch, Angela Walker, Isao Shiraishi, Kenneth D. R. Setchell, Erik Schaefer, Jan Kajstura, Piero Anversa, Mark A. Sussman

    —Cardiovascular disease risk is higher in men than women, but the basis for this discrepancy remains controversial. Estrogenic stimulation of the myocardium or isolated cardiomyocytes has been purported to exert multiple beneficial effects associated with inhibition of maladaptive responses to pathogenic insults. This report describes a significant difference between the sexes in myocardial activation of Akt, a protein kinase that regulates a broad range of physiological responses including metabolism, gene transcription, and cell survival. We find that young women possess higher levels of nuclear-localized phospho-Akt 473 relative to comparably aged men or postmenopausal women. Both localization of phospho-Akt 473 in myocardial nuclei of sexually mature female mice versus males and Akt kinase activity in nuclear extracts of hearts from female mice versus males are elevated. Cytosolic localization of phospho-forkhead, a downstream nuclear target of Akt, is also increased in female relative to male mice, suggesting a potential mechanism for cardioprotective nuclear signaling resulting from Akt activation. Phospho-Akt 473 levels and localization at cardiac nuclei are similarly increased in transgenic mice with myocardium-specific expression of insulin-like growth factor I, a proven stimulus for Akt activation. Phospho-Akt 473 is also localized to the nucleus of cultured cardiomyocytes after exposure to 17β-estradiol or genistein (a phytoestrogen in soy protein–based diets), and neonatal exposure of litters to genistein elevated nuclear phospho-Akt 473 localization. The activation of Akt in a gender-dependent manner may help explain differences observed in cardiovascular disease risk between the sexes and supports the potential beneficial effects of estrogenic stimulation.


  • Open Access

    Altered focal adhesion regulation correlates with cardiomyopathy in mice expressing constitutively active rac1

    by Mark A. Sussman, Sara Welch, Angela Walker, Raisa Klevitsky, Timothy E. Hewett, Robert L. Price, Erik Schaefer, Karen Yager

    The ras family of small GTP-binding proteins exerts powerful effects upon cell structure and function. One member of this family, rac, induces actin cytoskeletal reorganization in nonmuscle cells and hypertrophic changes in cultured cardiomyocytes. To examine the effect of rac1 activation upon cardiac structure and function, transgenic mice were created that express constitutively activated rac1 specifically in the myocardium. Transgenic rac1 protein was expressed at levels comparable to endogenous rac levels, with activation of the rac1 signaling pathway resulting in two distinct cardiomyopathic phenotypes: a lethal dilated phenotype associated with neonatal activation of the transgene and a transient cardiac hypertrophy seen among juvenile mice that resolved with age. Neither phenotype showed myofibril disarray and hypertrophic hearts were hypercontractilein working heart analyses. The rac1 target p21-activated kinase translocated from a cytosolic to a cytoskeletal distribution, suggesting that rac1 activation was inducing focal adhesion reorganization. Corroborating results showed altered localizations of src in dilated cardiomyopathy and paxillin in both cardiomyopathic phenotypes. This study, the first examination of rac1-mediated cardiac effects in vivo, demonstrates that dilation and hypertrophy can share a common molecular origin and presents evidence that both timing and concurrent signaling from multiple pathways can influence cardiac remodeling.


  • Pathogenesis of Dilated Cardiomyopathy

    by Mark A. Sussman, Sara Welch, Natalie Gude, Philip R. Khoury, Steven R. Daniels, Darryl Kirkpatrick, Richard A. Walsh, Robert L. Price, Hae W. Lim, Jeffery D. Molkentin


  • Altered Expression of Tropomodulin in Cardiomyocytes Disrupts the Sarcomeric Structure of Myofibrils

    by Mark A. Sussman, Susanna Baqué, Chang-Sub Uhm, Mathew P. Daniels, Robert L. Price, David Simpson, Louis Terracio, Larry Kedes

    —Tropomodulin is a tropomyosin-binding protein that terminates “pointed-end” actin filament polymerization. To test the hypothesis that regulation of tropomodulin:actin filament stoichiometry is critical for maintenance of actin filament length, tropomodulin levels were altered in cells by infection with recombinant adenoviral expression vectors, which produce either sense or antisense tropomodulin mRNA. Neonatal rat cardiomyocytes were infected, and sarcomeric actin filament organization was examined. Confocal microscopy indicated that overexpression of tropomodulin protein shortened actin filaments and caused myofibril degeneration. In contrast, decreased tropomodulin content resulted in the formation of abnormally long actin filament bundles. Despite changes in myofibril structure caused by altered tropomodulin expression, total protein turnover of the cardiomyocytes was unaffected. Biochemical analyses of infected cardiomyocytes indicated that changes in actin distribution, rather than altered actin content, accounted for myofibril reorganization. Ultrastructural analysis showed thin-filament disarray and revealed the presence of leptomeres after tropomodulin overexpression. Tropomodulin-mediated effects constitute a novel mechanism to control actin filaments, and our findings demonstrate that regulated tropomodulin expression is necessary to maintain stabilized actin filament structures in cardiac muscle cells.


  • Open Access

    Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice.

    by M A Sussman, S Welch, N Cambon, R Klevitsky, T E Hewett, R Price, S A Witt, T R Kimball

    Loss of myofibril organization is a common feature of chronic dilated and progressive cardiomyopathy. To study how the heart compensates for myofibril degeneration, transgenic mice were created that undergo progressive loss of myofibrils after birth. Myofibril degeneration was induced by overexpression of tropomodulin, a component of the thin filament complex which determines and maintains sarcomeric actin filament length. The tropomodulin cDNA was placed under control of the alpha-myosin heavy chain gene promoter to overexpress tropomodulin specifically in the myocardium. Offspring with the most severe phenotype showed cardiomyopathic changes between 2 and 4 wk after birth. Hearts from these mice present characteristics consistent with dilated cardiomyopathy and a failed hypertrophic response. Histological analysis showed widespread loss of myofibril organization. Confocal microscopy of isolated cardiomyocytes revealed intense tropomodulin immunoreactivity in transgenic mice together with abnormal coincidence of tropomodulin and alpha-actinin reactivity at Z discs. Contractile function was compromised severely as determined by echocardiographic analyses and isolated Langendorff heart preparations. This novel experimentally induced cardiomyopathy will be useful for understanding dilated cardiomyopathy and the effect of thin filament-based myofibril degeneration upon cardiac structure and function.